Every material Form 8-K ANAVEX LIFE SCIENCES CORP. has filed with the SEC since October 20, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., who had served as interim CEO since May 4, 2026, as President and Chief Executive Officer effective immediately, and added her to the Board. The Board reduced its size from six to five seats and is searching for an additional independent director. Her base salary remains $500,000 with an anticipated bonus of 30% of base salary, and the Board plans to review her employment agreement; the filing contains no financial results.
Appointed CEO and President effective immediately, with appointment dated November 1, 2026
Served as interim CEO since May 4, 2026; previously Senior Vice President, Clinical Development from November 2023 to May 2025
Annual base salary remains $500,000; anticipated bonus is 30% of base salary
Board reduced from six to five seats; search underway for an independent director to fill the fifth seat
Three Anavex directors, including Chair Jiong Ma, resigned effective October 28, 2026, each citing views on strategy not aligned with the Board and management. The Board then reconstituted its audit, compensation and nominating committees on November 1, 2026, with new chairs and members.
Jiong Ma (Chair), Gautam Patel and Adrian Senderowicz resigned from the Board effective October 28, 2026
Ma and Patel cited strategic views not aligned with the Board and management; Patel and Senderowicz cited strategy to execute the business plan
Dr. Claus van der Velden chairs the Audit Committee; Dr. Peter Donhauser chairs the Compensation Committee; Dr. Axel Paeger chairs Nominating & Corporate Governance
Resignation letters are filed as Exhibits 17.1, 17.2 and 17.3
Anavex said it has finished clinical conduct of two pharmacology studies of blarcamesine, an ADME study and a DDI study, both in healthy volunteers. The company said full safety and pharmacokinetic data analysis is still ongoing, and it expects the data to support its FDA-focused development program.
DDI study: last participant completed at the end of September 2026; 65 participants, all received 30 mg
ADME study: last participant completed in mid-October 2026; 8 participants, all received 30 mg
Preliminary observations show no serious adverse events reported; full analysis ongoing
FDA meeting planned for November 2026 on adding pediatric participants to the Rett syndrome Phase 3 study
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ANAVEX LIFE SCIENCES CORP. filing is on SEC EDGAR ↗. 8-K briefs of other companies →